Abstract
Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.
| Original language | English |
|---|---|
| Pages (from-to) | 353-358 |
| Number of pages | 6 |
| Journal | Annals of Oncology |
| Volume | 19 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2008 |
Fingerprint
Keywords
- AFP
- Cirrhosis
- HCC
- IL-6
- Tumor markers
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. / Porta, C.; De Amici, M.; Quaglini, S.; Paglino, C.; Tagliani, F.; Boncimino, A.; Moratti, R.; Corazza, G. R.
In: Annals of Oncology, Vol. 19, No. 2, 02.2008, p. 353-358.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
AU - Porta, C.
AU - De Amici, M.
AU - Quaglini, S.
AU - Paglino, C.
AU - Tagliani, F.
AU - Boncimino, A.
AU - Moratti, R.
AU - Corazza, G. R.
PY - 2008/2
Y1 - 2008/2
N2 - Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.
AB - Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.
KW - AFP
KW - Cirrhosis
KW - HCC
KW - IL-6
KW - Tumor markers
UR - http://www.scopus.com/inward/record.url?scp=38849106118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38849106118&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdm448
DO - 10.1093/annonc/mdm448
M3 - Article
C2 - 17962206
AN - SCOPUS:38849106118
VL - 19
SP - 353
EP - 358
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 2
ER -